Cost-effectiveness of GRAZAX® for prevention of grass pollen induced rhinoconjunctivitis in Southern Europe

Respiratory Medicine

Volumn 101, Issue 9, 2007, Pages 1885-1894

  Canonica, G W ^a   Poulsen, P B ^b   Vestenbaek U ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b MUUSMANN Research and Consulting   (Denmark)

^c ALK ABELLÓ   (Denmark)

Author keywords

Allergen specific immunotherapy; Cost effectiveness; Grass allergen tablet; Grass pollen allergy; QALY; Rhinoconjunctivitis

Indexed keywords

AIRCORT SPRAY; ALLERGEN; ARTEMUR; BUDESONIDE; CYCLOCAPS; DELTACORTENE; FLUTICASONE; FLUTICASONE PROPIONATE; FRISTAMIN; GRAZAX; INALACOR; LORATADINE; PLACEBO; PREDNISOLONE; PREDNISONE; PULMICORT TOPINASAL; SALBUTAMOL; UNCLASSIFIED DRUG;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; GEOGRAPHIC DISTRIBUTION; HOME CARE; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; MULTICENTER STUDY; POLLEN ALLERGY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; RHINOCONJUNCTIVITIS;

ADOLESCENT; ADULT; AGED; ALLERGENS; CONJUNCTIVITIS, ALLERGIC; COST-BENEFIT ANALYSIS; DESENSITIZATION, IMMUNOLOGIC; DRUG COSTS; FEMALE; HEALTH RESOURCES; HUMANS; MALE; MIDDLE AGED; POACEAE; POLLEN; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RHINITIS, ALLERGIC, SEASONAL; TABLETS;

EID: 34547436393     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.05.003     Document Type: Article

References (51)

1. Bousquet J., van Cauwenberge P., Khaltaev N., and Aria workshop group; World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 108 Suppl 5 (2001) S147-S334
2. Marshall JB. European allergy white paper. Allergic diseases as a public health problem in Europe. The UCG Institute of Allergy, May 1997.
3. Bauchau V., and Durham S.R. Prevalence and rate of diagnosis of allergic rhinitis in Europe. Eur Respir J 24 (2004) 758-764
4. Galassi C., De Sario M., Biggeri A., et al. Changes in the prevalence of asthma and allergies among children and adolescents in Italy: 1999-2002. Pediatrics 117 (2006) 34-42
5. Royal College of Physicians. Allergy: the unmet need, a blueprint for better patient care, June 2003.
6. Linneberg A., Nielsen N.H., Frølund L., Madsen F., Dirksen A., and Jørgensen T. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy 57 (2002) 1048-1052
7. Corren J. The impact of allergic rhinitis on bronchial asthma. J Allergy Clin Immunol 101 (1998) 352-356
8. Grossman J. One airway, one disease. Chest 111 (1997) 6-11
9. EFA (European Federation of Allergy and Airway Diseases Patients Association). Results of the patient voice allergy survey. Impact of allergic rhinitis in Europe. Summary Report; 2005. 〈www.efanet.org/〉.
10. Bousquet J., et al. ARIA in the pharmacy: management of allergic rhinitis symptoms in the pharmacy. Allergic rhinitis and its impact on asthma. Allergy 59 (2004) 373-387
11. Bousquet J., Lockey R., Malling H.J., et al. Allergen specific immunotherapy: therapeutic vaccines for allergic diseases allergy, World Health Organization and American Academy of Allergy, asthma and immunology. Ann Allergy Asthma Immunol 81 5 (1998) 401-405
12. Varney V.A., Gaga M., Frew A.J., Aber V.R., Kay A.B., and Durham S.R. Usefulness of allergen specific immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 302 6771 (1991) 265-269
13. Walker S.M., Varney V.A., Gaga M., Jacobson M.R., and Durham S.R. Grass pollen allergen specific immunotherapy. Efficacy and safety during a 4-year follow-up study. Allergy 50 (1995) 405-413
14. Durham S.R., Walker S.M., Varga E.M., et al. Long-term clinical efficacy of grass-pollen allergen specific immunotherapy. N Engl J Med 34 7 (1999) 468-475
15. Di-Rienzo V., Marcucci F., Puccinelli P., et al. Long-lasting effect of sublingual allergen specific immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 33 2 (2003) 206-210
16. Möller C., Dreborg S., Ferdousi H.A., et al. Pollen allergen specific immunotherapy reduces the development of asthma in children with seasonal rhinitis. The PAT-study. J Allergy Clin Immunol 109 2 (2002) 251-256
17. Niggemann B., Jacobsen L., Dreborg S., et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61 7 (2006) 855-859
18. Valovirta E., Jacobsen L., Niggemann B., et al. A 3-year course of subcutaneous specific immunotherapy results in long-term prevention of asthma in children. Ten year follow-up on the PAT-study. J Allergy Clin Immunol 117 3 (2006) 721
19. Bousquet J, van Cauwenberge PB, Khaltaev N, et al. The management of allergic rhinitis symptoms in the pharmacy, Paris, October 23, 2002.
20. Canonica G.W., and Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 111 3 (2003) 437-448
21. Passalacqua G., Guerra L., Pasquali M., and Canonica G.W. Non-injection routes for allergen immunotherapy: focus on sublingual immunotherapy. Inflamm Allergy Drug Targets 5 1 (2006) 43-51
22. Berto P., Passalacqua G., Crimi N., et al. Economic evaluation of sublingual immunotherapy versus symptomatic treatment in adults with pollen-induced respiratory allergy: the SPAI study. Ann Allergy Asthma Immunol 97 5 (2006) 615-621
23. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., and Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 117 (2006) 802-809
24. Dahl R., Stender A., and Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 61 (2006) 185-190
25. Rak S., Yang W.H., Pedersen M.R., and Durham S.R. Once-daily sublingual allergen-specific immunotherapy improves quality of life in patients with grass pollen-induced allergic rhinoconjunctivitis: a double-blind, randomised study. Qual Life Res 16 (2007) 191-201
26. Dahl R., Kapp A., Colombo G., et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablet for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 118 (2006) 434-440
27. Capri S., Ceci A., Terranova L., Merlo F., Mantovani L., and Members of IGPS. Guidelines for economic evaluation in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J 35 (2001) 189-201
28. Garattini L., Grilli R., Scopelliti D., and Mantovani L. A proposal for Italian Guidelines in pharmacoeconomics. Pharmacoeconomics 7 (1995) 1-6
29. Rovira J., and Antoñanzas F. Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation. Pharmacoeconomics 8 3 (1995) 245-252
30. Collége des Èconomistes de la Santé (CES). French guidelines for the economic evaluation of health care technologies, September 2004.
31. ALK-Abelló. GT-08 Integrated clinical trial report, pollen season 2005. Final 16, October 2005.
32. Drummond M.F., Sculpher M.J., Torrance G.W., O′Brien B., and Stoddart G.L. Methods for the economic evaluation of health care programmes. third ed (2005), Oxford Medical Publications, Oxford University Press, Oxford
33. Mosbech H., and Østerballe O. Does the effect of allergen specific immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 43 7 (1988) 523-529
34. Degli Esposti E., Berto P., Ruffo P., Buda S., Degli Esposti L., Sturani A., and Pandora Study Group. The PANDORA project: results of the cost of illness analysis. J Hum Hypertension 15 5 (2001) 329-334
35. Lindgren B., Sears M.R., Campbell M., Villasante C., Huang S., Lindh A., et al. Cost-effectiveness of formoterol and salbutamol as asthma reliever medication in Sweden and Spain. Int J Clin Practice 59 1 (2005) 62-68
36. Pinotti M, Vercilli F. Nuovo nomenclatore tariffario delle prestazioni specialistiche ambulatoriali. Direzione Medica di Presidio; 2004.
37. Serra-Batles J., Plaza V., Morejon E., and Comella A. Brugues J: cost of asthma according to the degree of severity. Eur Respir J 12 6 (1998) 1322-1326
38. Van Ganse E., Laforest L., Pietri G., et al. Persistent asthma: disease control, resource utilisation and direct costs. Eur Respir J 20 2 (2002) 260-267
39. Linneberg A., Nielsen N.H., Madsen F., Frølund L., Dirksen A., and Jørgensen T. Secular trends of allergic asthma in Danish adults. The Copenhagen Allergy Study. Respir Med 95 (2001) 258-264
40. Novembre E., Galli E., Landi F., et al. Co-seasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 114 (2004) 851-857
41. Antonicelli L., Bucca C., Neri M., et al. Asthma severity and medical resource utilisation. Eur Respir J 23 (2004) 723-729
42. Stock S., Redaelli M., Luengen M., Wendland G., Civello D., and Lauterbach K.W. Asthma: prevalence and cost of illness. Eur Respir J 25 (2005) 47-53
43. Heyse J.F., Cook J.R., and Carides G.W. Statistical considerations in analysing health care resource utilization and cost data. In: Drummond M., and McGuire A. (Eds). Economic evaluation in health care. Merging theory with practice (2001), Oxford University Press [Chapter 9]
44. Coons S.J., Rao S., Keininger D.L., and Hays R.D. A comparative review of generic quality-of-life instruments. Pharmacoeconomics 17 1 (2000) 13-35
45. Brooks R. EuroQol: the current state of play. Health Policy 37 1 (1996) 53-72
46. Instituto Nacional de Meteorologia. El año más seco, Noticias; 2006. 〈http://www.inm.es/〉.
47. Gonzáles Minero F.J., Candau P., Thomás C., and Morales J. Airborne grass (Poaceae) pollen in southern Spain. Results of a 10-year study (1987-1996). Allergy 53 (1998) 266-274
48. Sculpher M. The use of quality-adjusted life-years in cost-effectiveness studies. Allergy 61 (2006) 527-530
49. Guide to the methods of technology appraisal. National Institute of Clinical Excellence, April 2004.
50. Conference report, Scottish medicines consortium completes four year's work, vol. 10(1). IMS Health, PHARMA Pricing & Reimbursement; 2006.
51. Donahue J.G., Greineder D.K., Connor-Lacke L., Canning C.F., and Platt R. Utilization and cost of immunotherapy for allergic asthma and rhinitis. Ann Allergy Asthma Immunol 82 (1999) 339-347